Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030

  • No. of Pages: 240
  • Publish Date: June-2024
  • Category: Pharmaceutical and Healthcare
Electronic Access Single User
$3000
CD ROM Delivery
$4800
Hard Copy Delivery
$5100
Electronic Access Multi User
$6000

Buy USD 20,000 Worth Of Reports (Single User/Multi User License) In USD 8000 Only

Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions:

 

  • Number Of Gamma Delta T Cell Therapies In Trials: > 30 Therapies
  • US and China Dominating Clinical Trials Landscape: > 20 Therapies
  • Global Gamma Delta T Cell Therapy Clinical Trials Insight By Company, Country, Indication and Phase
  • Gamma Delta T Cell Therapy Future Market Opportunity By Different Cancers
  • Insight On Clinical Platforms for Evolving Gamma Delta T Cell Therapy: > 10 Platforms By Companies
  • Ongoing Clinical Research and Development Trends By Different Cancers
  • Insight On 12 Companies Developing Gamma Delta T Cell Therapies

 

After vicennium of futuristic T cells entrenched immunotherapy dominating the treatment landscape of cancer arena, there is a prerequisite to branch out cancer immunotherapy realm by developing other state-of-the-art therapies. But in spite of that, this led to discovery of other T cells receptors, such as gamma delta T cells, alpha-beta T cell and others. Consecutively, finding of gamma delta T cells based immunotherapy (also recognized as andgamma;anddelta; T cells), it was further pragmatic that developing gamma delta T cells based immunotherapies will aid to offer a innovatory treatment for cancer along with other disorders, including viral infections, autoimmune and inflammation.

 

With respect to KuicK Research statistics, the global clinical conduit of gamma delta T cells based immunotherapy comprises of 30 drugs (as of June 2024), several of which are in preclinical stage as well as majority of research and development along with technological advancement in in this sector is ongoing in the US and China region. Albeit, no drug has penetrated into the commercial market to treat cancer or other ailments; however, as soon as one drug will get approved will aid to launch other gamma delta T cells based immunotherapy into market and clenches potential to become a multimillionaire market in imminent.

    

One of the strategic prime movers that bestow to bourgeon the growth of gamma delta T cells based immunotherapy market is the rise in preclinical and clinical studies. Over the preceding decennium, the sphere of global gamma delta T cells based immunotherapy market has witnessed the development of several novel, innovative as well as advanced competitors. For instance, a clinical-stage biotechnology company in US, Acepodia Biotech has developed 2 contenders, ACE1708 as well as ACE2016 to treat solid tumor expressing PD-L1 accompanied with EGFR expressing tumors. 

 

Coupled with this, the presences of various stakeholders in conjugation with investors from giant pharma companies accompanied with biotech companies, such as Bristol Myers Squibb, TC Biopharm, PersonGen BioTherapeutics, In8bio, Kiromic BioPharma, Immatics, Legend Biotech, Innate Pharma, Ever Supreme Bio Technology, Editas Medicine, CytoMed Therapeutics, Acepodia Biotech and other have bestowed to transform the treatment paradigm by developing up-to-the-minute gamma delta T cells based immunotherapy worldwide. Amid all these companies, PersonGen BioTherapeutics is the frontrunner in this segment as the company is developing 5 allogeneic UCAR- andgamma;anddelta;1 T cell therapy for the treatment of autoimmune, T cell malignancies and other solid tumors. The presences of giant pharmaceuticals aid to conduct multitudinous clinical trials in gamma delta T cells based immunotherapy space.   

 

Just as importantly, an inclining market trend towards developing avant-garde global gamma delta T cells based immunotherapy, such as developing gamma-delta gene editing based immunotherapy, is gaining spotlight amid healthcare professionals. For instance, a biotech company based in Germany, Immatics has collaborated with Bristol Myers Squibb and Editas Medicine in order To syndicate gamma-delta T cell based adoptive cell therapies in addition to gene editing for the treatment of cancer.

 

Until now, no gamma delta T cells based immunotherapies has been approved in global market; nevertheless, it can be anticipated that a handful of gamma delta T cells therapies will be launched into the market in approaching 5 to 7 years due to the fact that many gamma delta T cells based immunotherapies have received FDA designations which aid to accelerate the approval process. For instance, ADI-001 has gained utmost breakthrough as it has received FDA fast track designation for the potential treatment of relapsed/refractory B-cell non-Hodgkin lymphoma (NHL), in 2022, and relapsed/refractory class III or class IV lupus nephritis in June 2024. Overall, aforementioned illustrates clearly forecasts that the future of gamma delta T cells based immunotherapies will be propitious.        

Need custom market research solution? We can help you with that too.